Biotricity Inc. (BTCY): R&D Expense
$2.76M
Year ended 2026-03-31
$2.74M
Trailing 12 months to 2026-06-30
-5.1%
3-year compound annual growth
+6.1%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $2.76M | +28.2% | 2026-07-14, From 2025-04-01 |
| 2025-03-31 | $2.16M | -16.2% | 2026-07-14, From 2024-04-01 |
| 2024-03-31 | $2.57M | -20.4% | 2025-07-18, From 2023-04-01 |
| 2023-03-31 | $3.23M | +17.7% | 2024-06-27, From 2022-04-01 |
| 2022-03-31 | $2.74M | +33.3% | 2023-06-29, From 2021-04-01 |
| 2021-03-31 | $2.06M | +51.0% | 2022-07-14, From 2020-04-01 |
| 2020-03-31 | $1.36M | +4.1% | 2021-06-22, From 2019-04-01 |
| 2019-03-31 | $1.31M | n/c | 2020-07-15, From 2018-04-01 |
| 2018-03-31 | $1.76M | +54.8% | 2019-07-16, From 2017-04-01 |
| 2017-03-31 | $1.14M | n/a | 2018-07-13, From 2016-04-01 |
| No annual figure between 2015-12-31 and 2017-03-31. | |||
| 2015-12-31 | $1.14M | n/a | 2017-03-30, From 2015-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Biotricity Inc. (BTCY) | 2026-03-31 | $2.76M | +28.2% |
| Profound Medical Corp. (PROF) | 2025-12-31 | $20.60M | +21.4% |
| Allurion Technologies, Inc. (ALUR) | 2025-12-31 | $7.57M | -56.4% |
| Vivos Therapeutics, Inc. (VVOS) | 2025-12-31 | $100.0K | 0.0% |
| Nephros Inc (NEPH) | 2025-12-31 | $1.34M | +47.8% |
| Sonoma Pharmaceuticals, Inc. (SNOA) | 2026-03-31 | $2.27M | +25.2% |
| DarioHealth Corp. (DRIO) | 2025-12-31 | $13.79M | -43.0% |
| Nexgel, Inc. (NXGL) | 2025-12-31 | $2.0K | -97.4% |
| Baird Medical Investment Holdings Ltd (BDMD) | 2025-12-31 | $20.13M | +226.0% |
Compare BTCY, PROF, ALUR, VVOS side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗